Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. More Details
Reasonable growth potential with questionable track record.
Share Price & News
How has Avantor's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AVTR is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: AVTR's weekly volatility (4%) has been stable over the past year.
7 Day Return
US Life Sciences
1 Year Return
US Life Sciences
Return vs Industry: AVTR exceeded the US Life Sciences industry which returned 60.1% over the past year.
Return vs Market: AVTR exceeded the US Market which returned 36.5% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Avantor's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StWhat Type Of Shareholders Own The Most Number of Avantor, Inc. (NYSE:AVTR) Shares?
1 month ago | Simply Wall StAvantor (NYSE:AVTR) Shareholders Booked A 60% Gain In The Last Year
1 month ago | Simply Wall StIs Avantor, Inc.'s (NYSE:AVTR) ROE Of 5.3% Concerning?
Is Avantor undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: AVTR ($28.47) is trading above our estimate of fair value ($24.26)
Significantly Below Fair Value: AVTR is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: AVTR is poor value based on its PE Ratio (315.5x) compared to the US Life Sciences industry average (43x).
PE vs Market: AVTR is poor value based on its PE Ratio (315.5x) compared to the US market (21.2x).
Price to Earnings Growth Ratio
PEG Ratio: AVTR is poor value based on its PEG Ratio (7.6x)
Price to Book Ratio
PB vs Industry: AVTR is overvalued based on its PB Ratio (9.9x) compared to the US Life Sciences industry average (7.6x).
How is Avantor forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AVTR's forecast earnings growth (41.8% per year) is above the savings rate (2%).
Earnings vs Market: AVTR's earnings (41.8% per year) are forecast to grow faster than the US market (20% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: AVTR's revenue (5.2% per year) is forecast to grow slower than the US market (10.4% per year).
High Growth Revenue: AVTR's revenue (5.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AVTR's Return on Equity is forecast to be high in 3 years time (23.2%)
How has Avantor performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AVTR has a large one-off loss of $358.6M impacting its December 31 2020 financial results.
Growing Profit Margin: AVTR became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: AVTR has become profitable over the past 5 years, growing earnings by 4.4% per year.
Accelerating Growth: AVTR has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: AVTR has become profitable in the last year, making it difficult to compare its past year earnings growth to the Life Sciences industry (7.4%).
Return on Equity
High ROE: AVTR's Return on Equity (4.4%) is considered low.
How is Avantor's financial position?
Financial Position Analysis
Short Term Liabilities: AVTR's short term assets ($2.2B) exceed its short term liabilities ($1.2B).
Long Term Liabilities: AVTR's short term assets ($2.2B) do not cover its long term liabilities ($6.0B).
Debt to Equity History and Analysis
Debt Level: AVTR's debt to equity ratio (180.3%) is considered high.
Reducing Debt: Insufficient data to determine if AVTR's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: AVTR's debt is not well covered by operating cash flow (19.3%).
Interest Coverage: AVTR's interest payments on its debt are not well covered by EBIT (2.4x coverage).
What is Avantor current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AVTR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AVTR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AVTR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AVTR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AVTR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Michael Stubblefield (47 yo)
Mr. Michael Stubblefield is President, Chief Executive Officer and Director of Avantor, Inc. since 2014. He has been the Chief Executive Officer of Avantor Performance Materials LLC. since May 2014. Mr. St...
CEO Compensation Analysis
Compensation vs Market: Michael's total compensation ($USD17.00M) is above average for companies of similar size in the US market ($USD10.54M).
Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.
|Executive VP & CFO||2.17yrs||US$3.98m||0.044% |
|Executive Vice President of India||7.08yrs||US$3.29m||0.026% |
|Executive VP||0.17yr||no data||no data|
|Senior VP||1.75yrs||no data||0.0034% |
|Executive VP & Chief Information Officer||2.83yrs||no data||0.024% |
|Vice President of Investor Relations||0.92yr||no data||no data|
|Executive VP||3.17yrs||no data||0.020% |
|Senior Vice President of Global Communications & Brand||no data||no data||no data|
|Executive VP & Chief Human Resources Officer||0.17yr||no data||no data|
|Executive Vice President of Strategic Partners||3.25yrs||no data||0.020% |
|Executive Vice President of Biopharma Production||2.58yrs||US$3.52m||0.030% |
Experienced Management: AVTR's management team is considered experienced (2.6 years average tenure).
|Independent Director||0.75yr||no data||no data|
|Non Executive Chairman||11.08yrs||US$443.55k||0.39% |
|Director||11.08yrs||no data||no data|
|Independent Director||1.83yrs||US$269.38k||no data|
|Independent Director||1.42yrs||US$77.15k||no data|
|Independent Director||4.08yrs||US$292.50k||no data|
|Independent Director||0.83yr||no data||no data|
|Independent Director||2.25yrs||US$278.13k||no data|
|Director||6.08yrs||no data||no data|
|Director||2.25yrs||no data||no data|
Experienced Board: AVTR's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: AVTR insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Avantor, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Avantor, Inc.
- Ticker: AVTR
- Exchange: NYSE
- Founded: 1904
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$16.535b
- Shares outstanding: 580.80m
- Website: https://www.avantorsciences.com
Number of Employees
- Avantor, Inc.
- Radnor Corporate Center
- Building One
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|AVTR||NYSE (New York Stock Exchange)||Yes||Common Stock||US||USD||May 2019|
|AVTR||XNYS (New York Stock Exchange, Inc. Floor)||Yes||Common Stock||US||USD||May 2019|
|AVG||BST (Boerse-Stuttgart)||Yes||Common Stock||DE||EUR||May 2019|
|AVTR.PRA||NYSE (New York Stock Exchange)||6.25 PFD CNV SR||US||USD||May 2019|
|AVG||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||May 2019|
|AVTR||WBAG (Wiener Boerse AG)||Yes||Common Stock||AT||EUR||May 2019|
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Midd...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/03/02 00:19|
|End of Day Share Price||2021/03/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.